Horizon Pharma Price Target Raised to $11.00 at R. F. Lafferty (HZNP)
Equities researchers at R. F. Lafferty boosted their price objective on shares of Horizon Pharma (NASDAQ:HZNP) from $9.00 to $11.00 in a research report issued on Wednesday, American Banking News reports. The firm currently has a “buy” rating on the stock. R. F. Lafferty’s target price would indicate a potential upside of 29.41% from the stock’s previous close.
A number of other firms have also recently commented on HZNP. Analysts at Zacks upgraded shares of Horizon Pharma from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, January 7th. They now have a $8.80 price target on the stock. Separately, analysts at Piper Jaffray reiterated a “buy” rating on shares of Horizon Pharma in a research note to investors on Wednesday, November 20th. They now have a $7.00 price target on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Horizon Pharma from $7.00 to $10.00 in a research note to investors on Wednesday, November 20th. They now have a “buy” rating on the stock. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $9.47.
Horizon Pharma (NASDAQ:HZNP) traded up 18.34% on Wednesday, hitting $10.059. 9,288,579 shares of the company’s stock traded hands. Horizon Pharma has a 52-week low of $1.97 and a 52-week high of $9.13. The stock has a 50-day moving average of $7.8 and a 200-day moving average of $4.69. The company’s market cap is $662.5 million.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.22. The company had revenue of $31.50 million for the quarter, compared to the consensus estimate of $18.31 million. During the same quarter in the prior year, the company posted ($0.47) earnings per share. On average, analysts predict that Horizon Pharma will post $-0.85 earnings per share for the current fiscal year.
Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.